Improved
6121 HealthChanged
3792 LivesSaved
3577 Lives0 lives impacted in the last 24 hrs Learn More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn more, see:
Rivaroxaban as Effective as Warfarin for Stroke Prevention in Atrial Fibrillation
http://bit.ly/o0eUXR
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!